RedHill Biopharma Ltd. RedHill Biopharma Provides Progress Update on RHB104 Phase III Crohn's Disease Program and Introduces Option for Early Stop for Success in Q22017

An option for early stop for success for overwhelming efficacy has been introduced into the ongoing first Phase III study with RHB104 for Crohn's disease the "MAP US" study and analysis is ex...